http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
-
PolyPid receives FDA support for D-PLEX100 drug application submission
-
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
-
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
-
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
-
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
-
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
-
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
-
PolyPid to present phase 3 SHIELD II trial results at surgical conference
-
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
-
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
-
PolyPid completes israeli health ministry GMP inspection
-
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
-
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
-
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
-
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
-
PolyPid names Dr. Nurit Tweezer-Zaks as chief medical officer
-
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
-
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
-
PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment
-
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
-
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
-
PolyPid Ltd. (PYPD) to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
-
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
-
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
-
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
-
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
-
PolyPid to Participate in The Citizens Life Sciences Conference
-
PolyPid to Participate in the 37th Annual ROTH Conference
-
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
-
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
-
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
-
PolyPid Ltd. (PYPD) Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
-
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
-
PolyPid Ltd. (PYPD) Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
-
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
-
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
-
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
-
PolyPid Ltd. (PYPD) Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal C
-
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Su
-
PolyPid (PYPD) Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Inf
-
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Inf
-
PolyPid to Participate in Three Upcoming Fall Investor Conferences
-
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
-
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
-
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
-
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
